<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066027</url>
  </required_header>
  <id_info>
    <org_study_id>511-00-FB</org_study_id>
    <secondary_id>R01DE012872</secondary_id>
    <nct_id>NCT00066027</nct_id>
  </id_info>
  <brief_title>Effects of Low-Dose Doxycycline on Oral Bone Loss</brief_title>
  <official_title>Low-Dose Doxycycline Effects on Osteopenic Bone Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this clinical trial is to determine whether low-dose doxycycline can
      reduce alveolar bone density loss in postmenopausal osteopenic women with periodontitis and
      not on hormone replacement therapy (i.e., estrogen deficient).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this clinical trial is to determine whether low-dose doxycycline (LDD)
      can reduce alveolar bone density loss in postmenopausal osteopenic women with periodontitis
      and not on hormone replacement therapy (i.e., estrogen deficient). The effects of LDD on
      alveolar bone height loss, progressive periodontal attachment loss, systemic bone mineral
      density, gingival crevicular fluid biochemical markers of collagen degradation and bone
      resorption and serum biomarkers of bone formation, bone resorption and inflammation also will
      be assessed. In addition, another objective is to determine if the microbial effects obtained
      with LDD over two years are equivalent to a placebo control. This clinical trial involves two
      clinical sites: the University of Nebraska Medical Center College of Dentistry and Stony
      Brook University School of Dental Medicine. A total of 128 postmenopausal osteopenic women
      with periodontitis between the ages of 45 and 70 at the time of telephone screening will be
      randomized to LDD or placebo groups and subjects will be followed for two years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>alveolar bone density</measure>
    <time_frame>Baseline, one-year and two-year visits</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>low-dose doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose doxycycline (20 mg doxycycline hyclate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg doxycycline hyclate</intervention_name>
    <description>Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years</description>
    <arm_group_label>low-dose doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects in the placebo group took a placebo look-alike twice daily for two years.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be female, postmenopausal and not receiving estrogen replacement
             therapy.

          -  Subjects will be 45-70 years old at the time of telephone screening.

          -  Subjects will have osteopenia (T-score of -1.0 to -2.5) of the lumbar spine or femoral
             neck as determined by dual-energy absorptiometry (DEXA) scans.

          -  Subjects will have a history of generalized moderate-advanced periodontitis and will
             be undergoing periodontal maintenance.

          -  Subjects will be in good general health and willing to sign the IRB-approved consent
             form.

        Exclusion Criteria:

          -  Subjects will not have an allergy or hypersensitivity to tetracyclines.

          -  Subjects will not have diseases or take medications that affect the inflammatory or
             immune responses (e.g., chronic use of non-steroidal anti-inflammatory drugs) or bone
             remodeling (e.g., drugs such as prescription estrogens, bisphosphonates, calcitonin or
             steroids).

          -  Subjects will not have any medical condition requiring antibiotic premedication (e.g.,
             prosthetic heart valves, prosthetic joints, and mitral valve prolapse with
             regurgitation) for routine dental therapy.

          -  Subjects cannot have diabetes mellitus.

          -  Subjects cannot have had active periodontal therapy (quadrant scaling and root planing
             or periodontal surgery) within the past year.

          -  Subjects cannot have osteoporosis (T-score greater than -2.5) of the lumbar spine or
             femoral neck.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Payne, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNMC College of Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNMC College of Dentistry</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68583-0740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oral Biology and Pathology</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stoner JA, Payne JB. Interpretation of treatment effects in periodontal research: a note on the number needed to treat. J Can Dent Assoc. 2008 Jun;74(5):435-7.</citation>
    <PMID>18538066</PMID>
  </reference>
  <results_reference>
    <citation>Salminen A, Pussinen PJ, Payne JB, Stoner JA, Jauhiainen M, Golub LM, Lee HM, Thompson DM, Sorsa T. Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages. Inflamm Res. 2013 Jul;62(7):711-20. doi: 10.1007/s00011-013-0626-z. Epub 2013 May 7.</citation>
    <PMID>23649042</PMID>
  </results_reference>
  <results_reference>
    <citation>Payne JB, Nummikoski PV, Thompson DM, Golub LM, Stoner JA. The association between clinical and radiographic periodontitis measurements during periodontal maintenance. J Periodontol. 2013 Oct;84(10):1382-90. doi: 10.1902/jop.2012.120484. Epub 2012 Dec 3.</citation>
    <PMID>23205917</PMID>
  </results_reference>
  <results_reference>
    <citation>Gu Y, Walker C, Ryan ME, Payne JB, Golub LM. Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. J Oral Microbiol. 2012;4. doi: 10.3402/jom.v4i0.19227. Epub 2012 Oct 12.</citation>
    <PMID>23071896</PMID>
  </results_reference>
  <results_reference>
    <citation>Payne JB, Golub LM, Stoner JA, Lee HM, Reinhardt RA, Sorsa T, Slepian MJ. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. J Am Dent Assoc. 2011 Mar;142(3):262-73.</citation>
    <PMID>21357860</PMID>
  </results_reference>
  <results_reference>
    <citation>Payne JB, Golub LM. Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol Res. 2011 Feb;63(2):121-9. doi: 10.1016/j.phrs.2010.10.006. Epub 2010 Oct 16. Review.</citation>
    <PMID>20937388</PMID>
  </results_reference>
  <results_reference>
    <citation>Golub LM, Lee HM, Stoner JA, Reinhardt RA, Sorsa T, Goren AD, Payne JB. Doxycycline effects on serum bone biomarkers in post-menopausal women. J Dent Res. 2010 Jun;89(6):644-9. doi: 10.1177/0022034510363367. Epub 2010 Mar 26.</citation>
    <PMID>20348487</PMID>
  </results_reference>
  <results_reference>
    <citation>Reinhardt RA, Stoner JA, Golub LM, Lee HM, Nummikoski PV, Sorsa T, Payne JB. Association of gingival crevicular fluid biomarkers during periodontal maintenance with subsequent progressive periodontitis. J Periodontol. 2010 Feb;81(2):251-9. doi: 10.1902/jop.2009.090374.</citation>
    <PMID>20151804</PMID>
  </results_reference>
  <results_reference>
    <citation>Golub LM, Lee HM, Stoner JA, Sorsa T, Reinhardt RA, Wolff MS, Ryan ME, Nummikoski PV, Payne JB. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol. 2008 Aug;79(8):1409-18. doi: 10.1902/jop.2008.070623 .</citation>
    <PMID>18672990</PMID>
  </results_reference>
  <results_reference>
    <citation>Walker C, Puumala S, Golub LM, Stoner JA, Reinhardt RA, Lee HM, Payne JB. Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results. J Periodontol. 2007 Aug;78(8):1590-601.</citation>
    <PMID>17668979</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2003</study_first_submitted>
  <study_first_submitted_qc>August 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2003</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Jeffrey Payne</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>periodontitis, metabolic bone diseases, doxycycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

